Angélica Castaño Navarro

Dr. Angélica Castaño Navarro

University of Seville, Seville, Spain
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2000 in Neurobiology of Disease
Verified
Journal Article
Closed access
ACAntonio J. Herrera Carmona
Antonio J. Herrera Carmona
ANAngélica Castaño Navarro
Angélica Castaño Navarro
JVJose Luis Venero
Jose Luis Venero
JCJ. Cano
J. Cano
AMA. Machado
A. Machado

1 April 1998 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
ANAngélica Castaño Navarro
Angélica Castaño Navarro
ACAntonio J. Herrera Carmona
Antonio J. Herrera Carmona
JCJ. Cano
J. Cano
AMA. Machado
A. Machado
The pathogenesis of Parkinson's disease is still poorly understood. To address the hypothesis that immunemediated events, such as microglial activation, may be involved in the dopaminergic neurodegeneration, we have studied the effect that intranigral injection of the immunostimulant lipopolysaccharide has on monoaminergic neurotransmitters in rats. Activation of microglial cells, visualized by immunohistochemistry with a specific monoclonal antibody, was already obvious 2 days after injection. In relation to the biochemical parameters studied, we found a significant decrease of dopamine levels in both the substantia nigra and striatum up to at least 21 days after intranigral injection of lipopolysaccharide. This result was supported by the decrease in tyrosine hydroxylase activity and the loss of tyrosine hydroxylase‐positive neuronal bodies, shown by immunohistochemistry. These alterations of the dopaminergic system did not reverse during the interval studied (21 days); conversely, the serotoninergic system suffered only transient damage. In addition, we found that the neurotoxic effect of lipopolysaccharide was not mediated by nitric oxide. Based on our results we suggest that the nigrostriatal dopaminergic system is susceptible to damage by inflammatory events and that these may be implicated in neurodegeneration processes such as Parkinson's disease.


1 July 2006 in Neurobiology of Aging
Verified
Journal Article
Closed access
MGM. Paz Gavilán
M. Paz Gavilán
JVJosé Vela
José Vela
ANAngélica Castaño Navarro
Angélica Castaño Navarro
BRBlanca Ramos
Blanca Ramos
JRJuan C. del Río
Juan C. del Río
DRDiego Ruano
Diego Ruano

5 December 2012 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
MCManila Candiracci
Manila Candiracci
EPElena Piatti
Elena Piatti
MDMaría Dominguez-Barragán
María Dominguez-Barragán
DGDaniel García-Antrás
Daniel García-Antrás
BMBruno Rodriguez Morgado
Bruno Rodriguez Morgado
ANAngélica Castaño Navarro
Angélica Castaño Navarro

7 June 1997 in Neurochemistry International
Verified
Journal Article
Closed access
ANAngélica Castaño Navarro
Angélica Castaño Navarro
AAA Ayala
A Ayala
JRJosé Rodríguez-Gómez
José Rodríguez-Gómez
ACAntonio J. Herrera Carmona
Antonio J. Herrera Carmona
JCJ Cano
J Cano
AMA Machado
A Machado